AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2957971
Drug: Dichloromethylene diphosphonate
RxNorm normalized name: (dichloromethylene)diphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloromethylene diphosphonate (300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days)
Trial: 22517782
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (CT)
Trial: 26950307
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose (LD) adalimumab weekly
Trial: 26950307
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose (HD) adalimumab weekly
Trial: 23758800
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (2 μg/kg, n = 10)
Trial: 12969204
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 15 mg/kg and 30 mg/kg
Trial: 11050638
Drug: Mangafodipir trisodium
RxNorm normalized name: Mangafodipir trisodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangafodipir trisodium (MnDPDP) injection (5 micromol/kg IV)
Trial: 22938019
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the CORAL Decision Aid (DA) in addition to treatment as usual
Trial: 15699482
Drug: OSI‐211 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI‐211 1.8 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1, 2, and 3 every 3 weeks
Trial: 15699482
Drug: OSI‐211 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI‐211 2.4 mg/m(2)/d administered by 30‐minute intravenous infusion on days 1 and 8 every 3 weeks
Trial: 15699482
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (OSI‐211 1.8 mg/m(2)/d)
Trial: 15699482
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (OSI‐211 2.4 mg/m(2)/d)
Trial: 12475836
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group (7.5 mg albuterol)
Trial: 12475836
Drug: Multidose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose group (2.5 mg albuterol, three doses)
Trial: 7486842
Drug: Fluoxetine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (group A)
Trial: 2102064
Drug: PDRN 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN 5 mg ovules
Trial: 29629665
Drug: Multiphasic cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic cancer screening (including PSA, digital rectal examination, chest x‐ray, flexible sigmoidoscopy, CA125, transvaginal ultrasound)
Trial: 24430035
Drug: Cytoflavin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (2 pills twice per day, total 4 pills daily)
Trial: 24430035
Drug: Standard antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressant therapy (control)
Trial: 20658369
Drug: One-day bowel
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day bowel preparation with probiotics
Trial: 20658369
Drug: 3-day conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day conventional bowel preparation
Trial: 18721256
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered after meals for 3 months
Trial: 18721256
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered before meals for 3 months
Trial: 16845576
Drug: Denver Model
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Denver Model (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Trial: 16845576
Drug: PROMPT (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROMPT (12 1-h weekly sessions of therapy and daily 1-h home intervention)
Trial: 11433855
Drug: Air abrasion
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air abrasion treatment of questionable incipient carious lesions
Trial: 11433855
Drug: Air abrasion
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air abrasion treatment of carious lesions in control group
Trial: 11433855
Drug: Preventive resin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive resin-based composite restorations in treatment group
Trial: 11433855
Drug: Sealants in
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants in treatment group
Trial: 7508071
Drug: Aprotinin (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high-dose, up to 7 million KIU)
Trial: 1313484
Drug: Fibre (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre (7 g/day)
Trial: 629867
Drug: PUVA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA plus topical corticosteroids
Trial: 31280648
Drug: Augmentation ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation ratio (+7.0%)
Trial: 26433183
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment (8 days) with prednisone
Trial: 23380186
Drug: GM-CSF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (2 ng/mL in embryo culture medium)
Trial: 21552714
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (scaling and root planning, professional prophylaxis, oral hygiene instruction)
Trial: 21552714
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (received professional prophylaxis and oral hygiene instruction during pregnancy, referred for treatment after delivery)
Trial: 19407444
Drug: terutroban (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terutroban (30 mg/day)
Trial: 12361194
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg once daily (o.d.)
Trial: 12361194
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg o.d.
Trial: 12361194
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg o.d.
Trial: 9719120
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (NT)
Trial: 8109547
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (0.5 to 1.0 g twice daily)
Trial: 8109547
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg at bedtime)
Trial: 25880012
Drug: CIGB-300 70
RxNorm normalized name: CIGB 300
DrugBank: CIGB 300 (DB16464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIGB-300 70 mg
Trial: 25880012
Drug: CIGB-300 35
RxNorm normalized name: CIGB 300
DrugBank: CIGB 300 (DB16464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIGB-300 35 mg
Trial: 23591160
Drug: Pemetrexed as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed as second-line treatment after observation
Trial: 23591160
Drug: Pemetrexed as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed as second-line treatment after gemcitabine maintenance
Trial: 23591160
Drug: Pemetrexed as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed as second-line treatment after erlotinib maintenance
Trial: 21114584
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg, intravenous)
Trial: 17301091
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of montelukast
Trial: 11507800
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B D8
Trial: 22624652
Drug: Individualized nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized nutritional care with visits from a trained nutritionist 4-8 times at home, tailored nutritional care, protein and nutrient-enriched complementary drinks, vitamin D 20 μg/day for one year
Trial: 15700052
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg daily) plus calcium (1000 mg daily)
Trial: 7724182
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (three or more daily insulin injections or continuous subcutaneous insulin infusion, guided by four or more glucose tests daily)
Trial: 27207886
Drug: 4-week oral
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week oral administration of S-1 (80-120 mg/body/day) followed by a 2-week rest (Group A)
Trial: 27207886
Drug: 2-week oral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week oral administration of S-1 (80-120 mg/body/day) followed by a 1-week rest (Group B)
Trial: 23963633
Drug: 28.2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28.2 μg teriparatide
Trial: 23963633
Drug: Placebo (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.4 μg teriparatide)
Trial: 23358401
Drug: 400 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 Gy absorbed thyroid dose (Group C)
Trial: 23358401
Drug: 200 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 Gy absorbed thyroid dose (Group B)
Trial: 23358401
Drug: 100 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 Gy absorbed thyroid dose (Group A)
Trial: 16337459
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg twice daily
Trial: 16008596
Drug: Thymoglobulin (TG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (TG) induction therapy (1.5 mg/kg/dose during the anhepatic period and QOD x2 doses)
Trial: 16008596
Drug: Thymoglobulin (TG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (TG) induction therapy
Trial: 3079781
Drug: Encainide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide 25 mg four times/day
Trial: 3079781
Drug: Quinidine 200
RxNorm normalized name: quiNIDine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 200 mg four times/day
Trial: 3079781
Drug: Encainide 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide 50 mg four times/day (after dose adjustment)
Trial: 3079781
Drug: Quinidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 400 mg four times/day (after dose adjustment)
Trial: 26304041
Drug: rLH 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 150 IU/day added to rFSH 300 IU/day and GnRH antagonist 0.25 mg/day
Trial: 26304041
Drug: rFSH 300
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rFSH 300 IU/day and GnRH antagonist 0.25 mg/day (Control)
Trial: 23788002
Drug: ω-3 FA-enriched
RxNorm normalized name: folic acid 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 FA-enriched oral nutrition supplement (200 mL twice daily providing 2.0 g EPA and 1.0 g DHA per day)
Trial: 23788002
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral nutrition supplement (ONS)
Trial: 24531662
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care 3 times weekly in addition to usual medical care
Trial: 21767441
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Lu AA21004
Trial: 21767441
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Lu AA21004
Trial: 21767441
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg venlafaxine XR
Trial: 12478879
Drug: Myo-inositol, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol, 12 g daily
Trial: 12478879
Drug: Placebo (d‐glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (d‐glucose, 12 g daily)
Trial: 10531773
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of purified Hepatitis B Surface Antigen (Euvax B, LG Chemicals) by i.m. injection in the deltoid (Group A)
Trial: 8915800
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) and a soft contact lens
Trial: 8915800
Drug: Long-term NSAID
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term NSAID administration
Trial: 8915800
Drug: Management suggestions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management suggestions for severe haze and regression and steroid-induced elevated intraocular pressure
Trial: 29972002
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (acupuncture, acupoint injection, auricular point pressing)
Trial: 29972002
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (oral mecobalamin, 0.5 mg, 3 times a day for 3 weeks)
Trial: 24485709
Drug: Active OIT
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active OIT (peanut flour; protein doses of 2-800 mg/day)
Trial: 19234106
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (n = 15, control)
Trial: 12881939
Drug: Daily exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposure to pacifiers
Trial: 7860469
Drug: Albendazole 15
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 15 mg/kg bodyweight/day for 30 days
Trial: 2064878
Drug: Fentanyl 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 4.5 micrograms ml‐1
Trial: 2064878
Drug: Adrenaline 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 4.5 micrograms ml‐1
Trial: 2064878
Drug: Adrenaline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline plus fentanyl (4.5 micrograms ml‐1 of each)
Trial: 7055401
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of tinidazole (1600 mg) and doxycycline (400 mg) before operation
Trial: 31044556
Drug: Ultralow dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow dose CT (100 Sn kV and 96 mA)
Trial: 31044556
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CT (110 kV and 50 mA)
Trial: 31522147
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment (quadrant scaling and root planing - Q-SRP)
Trial: 27732056
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic supplement, taken twice daily for 8 weeks.
Trial: 22839109
Drug: Diesel combustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel combustion particles inhaled during spontaneous breathing
Trial: 19708629
Drug: Brace and
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace and surgery treatment (BS group)
Trial: 19708629
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with no brace treatment (S group)
Trial: 15045532
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AB and BSM
Trial: 11976463
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Trial: 11976463
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Trial: 11976463
Drug: Daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and weekly iron therapy
Trial: 8079014
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine treatment
Trial: 31545388
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis based on patient-specific risk factors
Trial: 31545388
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of anticoagulant therapy perioperatively
Trial: 31545388
Drug: Topical emollients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical emollients and petroleum
Trial: 13679688
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between Immunotherapy and Control
Trial: 11203592
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA gel
Trial: 8385183
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril with 12.5 mg HCT
Trial: 8385183
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril with 25 mg HCT
Trial: 8385183
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ramipril with 12.5 mg HCT
Trial: 8385183
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ramipril with 25 mg HCT
Trial: 8385183
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ramipril plus HCT
Trial: 8385183
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg HCT
Trial: 27871236
Drug: Dexmedetomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine administered after spinal anesthesia (Group A)
Trial: 27871236
Drug: Dexmedetomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine administered before spinal anesthesia (Group B)
Trial: 24814039
Drug: Magnesium chloride
RxNorm normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium chloride (30 mL of MgCl2 5% solution) once daily for 3 months
Trial: 24814039
Drug: NaHCO3 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 0.1% solution (control) once daily for 3 months
Trial: 22739364
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400 mg/day)
Trial: 8529770
Drug: Danazol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (400 mg/day)
Trial: 1686422
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg QAM
Trial: 1686422
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg QHS
Trial: 1686422
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg BID
Trial: 6119512
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg 6‐hourly for adults and 40 mg/kg daily for children)
Trial: 26597740
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg/day elemental calcium)
Trial: 23374761
Drug: Home-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based occupational therapy for 10 weeks delivered by trained occupational therapists.
Trial: 23374761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no occupational therapy during the study period).
Trial: 9803586
Drug: AIK-C measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIK-C measles vaccine (4.0 log10pfu) administered at 6 months
Trial: 9803586
Drug: Schwarz vaccine
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz vaccine (3.7 log10pfu) given at 9 months